Tirzepatide (LY3298176): Molecular Characterization and Receptor Pharmacology — A Research Reference

Tirzepatide is a 39-amino-acid synthetic peptide engineered as a dual agonist at two incretin receptors [1]. Its most consequential design decision is the choice of backbone: the sequence is built on glucose-dependent insulinotropic polypeptide (GIP) rather than on GLP-1, with substitutions introduced to confer engagement at the GLP-1 receptor as well. Analogues in this space could in principle be constructed from either parent; the GIP-based construction is what distinguishes this molecule from GLP-1-derived agonists.

Three modification classes define it. Two α-aminoisobutyric acid (Aib) substitutions, at positions 2 and 13, provide protease resistance — Aib is a non-proteinogenic residue bearing two α-carbon methyl groups, and the position-2 substitution in particular obstructs dipeptidyl peptidase-4, which cleaves incretin peptides at the amino terminus [1, 6].

A C20 α,ω-dicarboxylic acid is conjugated to the lysine at position 20 through a spacer of γ-glutamic acid and two 8-amino-3,6-dioxaoctanoic acid units. The free distal carboxylate confers reversible albumin association; the hydrophilic spacer separates the lipid from the peptide backbone so that receptor engagement is preserved. The intact conjugate has a molecular weight of approximately 4,814 daltons.

The C-terminus is amidated, removing the negative charge a free carboxylate would carry at neutral pH.

The Two Target Receptors

GIPR is the receptor for glucose-dependent insulinotropic polypeptide, a 42-amino-acid incretin. It is a class B secretin-family G-protein-coupled receptor coupling principally to Gαs, with receptor activation stimulating adenylyl cyclase and raising intracellular cyclic AMP [4, 5].

GLP-1R is the receptor for glucagon-like peptide-1, a proglucagon-derived incretin, and is among the most extensively characterized class B GPCRs, with published cryo-electron microscopy structures of ligand-bound and G-protein-coupled states [7].

Published in-vitro characterization describes tirzepatide's activity at these two receptors as imbalanced and biased — two distinct pharmacological properties that are worth separating [2]. Imbalance refers to unequal relative potency across the two receptors, with reported characterization describing greater relative potency at GIPR than at GLP-1R. Bias refers to differential engagement of downstream transducers at a single receptor: at GLP-1R, the reported profile favours Gαs coupling over β-arrestin recruitment relative to the native ligand, which alters receptor internalization behaviour in vitro.

The distinction matters for characterization work, because a single potency figure at each receptor describes the first property and says nothing about the second. Ratio-tuning across receptors, and transducer-bias at each, are independent design variables in polyagonist research [1, 2, 6].

A cryo-electron microscopy structure of GIPR bound to tirzepatide has resolved the ligand-receptor interface directly, defining the peptide-binding groove and the contacts responsible for the molecule's engagement at that receptor [3].

Mass spectrometry confirms the intact molecular mass near 4,814 daltons. Because the acyl–spacer conjugate and the C-terminal amide each contribute defined increments, the measurement reports simultaneously on chain assembly, acylation, and terminal amidation — a free-acid C-terminus differs by approximately one dalton, and a di-acylated species by a further defined increment.

Reversed-phase HPLC resolves the main peak from related substances and yields the purity figure. Two related-substance classes are specific to this compound: positional acylation isomers, where the conjugate attached at an unintended residue, which carry identical mass and are invisible to mass measurement alone; and diastereomers arising from racemization during synthesis, likewise mass-identical. Both separate chromatographically, which is why the two methods are run in combination.

Deletion sequences, where a residue failed to couple, remain the dominant synthesis-related impurity class in a 39-residue chain.

Net peptide content accounts for counter-ions and residual water, determining how much peptide a nominal milligram figure represents.

Sealed lyophilized material is stable at ambient temperature for the duration of transit and requires no cold chain in shipping. On receipt, vials are refrigerated and kept out of direct light.

Reconstituted material is held refrigerated and used within the window the receiving facility's protocols specify, and repeated freeze–thaw cycling is avoided.

As with other acylated peptides, the lipid moiety confers amphiphilicity: the molecule associates with hydrophobic surfaces and accumulates at air–liquid interfaces, so agitation is minimised and low-binding labware is a reasonable default where small quantities are handled. At 39 residues with an appended lipid, the aggregation surface is larger than that of a short unmodified sequence.

Material supplied by HEEZ Research is research-grade and is not a pharmaceutical product. No manufacturing, labeling, or quality standards for an approved product apply to it. Research material is sold strictly for laboratory research use; it must not be administered to humans or animals. Researchers are responsible for compliance with all institutional and jurisdictional requirements governing research chemicals.

Each batch of research-grade tirzepatide is accompanied by an independent certificate of analysis specific to that lot.

Tirzepatide is a 39-residue dual incretin-receptor agonist built on a GIP rather than GLP-1 backbone, carrying Aib substitutions at positions 2 and 13, a C20 diacid conjugated to Lys20 through a γGlu–dioxaoctanoyl spacer, and an amidated C-terminus, with an intact mass near 4,814 daltons. It is characterized against GIPR and GLP-1R — two class B GPCRs coupling to Gαs — with reported in-vitro activity described as both imbalanced across the two receptors and biased in transducer engagement at GLP-1R. Analytical verification rests on mass confirmation of acylation and amidation, chromatographic resolution of positional isomers and diastereomers, and batch-specific net peptide content.